PURPOSE: The aim of this study was to assess differences in the presence, size, number and site of dilated cerebral Virchow-Robin spaces (VRSd) between patients with multiple sclerosis (MS) in the inactive phase and healthy controls, and between MS patients with disabling (MSd) or nondisabling (MSnd) disease. MATERIALS AND METHODS: The study was performed by retrospectively analysing the 3 T magnetic resonance studies of 40 MS patients and 30 healthy subjects (matched for age, education and gender). The data were analysed with MIPAV (Medical Image Processing, Analysis and Visualisation) software to assess for VRSd and with FSL SIENA-X to measure global cerebral atrophy (GCA) expressed as brain parenchyma fraction. RESULTS: The MS patients had significantly higher VRSd number (p < 0.011), area (p < 0.0073) and volume (p < 0.0071) than controls, with a marked increase for atypical sites (p < 0.0069) without significant intragroup differences between the disease forms (MSd vs MSnd). The number and size of VRSd did not correlate with GCA. CONCLUSIONS: Our results confirm previous reports regarding the increase in VRSd in nonactive phases of MS and support the immunological role of the VRS within the central nervous system. The lack of correlation between VRSd and the degree of GCA and their prevailing localisation in atypical sites in MS patients make VRSd a potential marker of inflammatory-demyelinating disease.
PURPOSE: The aim of this study was to assess differences in the presence, size, number and site of dilated cerebral Virchow-Robin spaces (VRSd) between patients with multiple sclerosis (MS) in the inactive phase and healthy controls, and between MSpatients with disabling (MSd) or nondisabling (MSnd) disease. MATERIALS AND METHODS: The study was performed by retrospectively analysing the 3 T magnetic resonance studies of 40 MSpatients and 30 healthy subjects (matched for age, education and gender). The data were analysed with MIPAV (Medical Image Processing, Analysis and Visualisation) software to assess for VRSd and with FSL SIENA-X to measure global cerebral atrophy (GCA) expressed as brain parenchyma fraction. RESULTS: The MSpatients had significantly higher VRSd number (p < 0.011), area (p < 0.0073) and volume (p < 0.0071) than controls, with a marked increase for atypical sites (p < 0.0069) without significant intragroup differences between the disease forms (MSd vs MSnd). The number and size of VRSd did not correlate with GCA. CONCLUSIONS: Our results confirm previous reports regarding the increase in VRSd in nonactive phases of MS and support the immunological role of the VRS within the central nervous system. The lack of correlation between VRSd and the degree of GCA and their prevailing localisation in atypical sites in MSpatients make VRSd a potential marker of inflammatory-demyelinating disease.
Authors: Matilde Inglese; Elan Bomsztyk; Oded Gonen; Lois J Mannon; Robert I Grossman; Henry Rusinek Journal: AJNR Am J Neuroradiol Date: 2005-04 Impact factor: 3.825
Authors: Y-C Zhu; C Dufouil; B Mazoyer; A Soumaré; F Ricolfi; C Tzourio; H Chabriat Journal: AJNR Am J Neuroradiol Date: 2011-02-24 Impact factor: 3.825
Authors: Renata Conforti; Mario de Cristofaro; Adriana Cristofano; Barbara Brogna; Angela Sardaro; Gioacchino Tedeschi; Sossio Cirillo; Alfonso Di Costanzo Journal: Neuroradiol J Date: 2016-01-11
Authors: S C Kolbe; L M Garcia; N Yu; F M Boonstra; M Clough; B Sinclair; O White; A van der Walt; H Butzkueven; J Fielding; M Law Journal: AJNR Am J Neuroradiol Date: 2022-02 Impact factor: 3.825
Authors: Alice Favaretto; Andrea Lazzarotto; Alice Riccardi; Stefano Pravato; Monica Margoni; Francesco Causin; Maria Giulia Anglani; Dario Seppi; Davide Poggiali; Paolo Gallo Journal: PLoS One Date: 2017-10-18 Impact factor: 3.240
Authors: Mackenzie T Langan; Derek A Smith; Gaurav Verma; Oleksandr Khegai; Sera Saju; Shams Rashid; Daniel Ranti; Matthew Markowitz; Puneet Belani; Nathalie Jette; Brian Mathew; Jonathan Goldstein; Claudia F E Kirsch; Laurel S Morris; Jacqueline H Becker; Bradley N Delman; Priti Balchandani Journal: Front Neurol Date: 2022-04-01 Impact factor: 4.086
Authors: Tobias Granberg; Thomas Moridi; Judith S Brand; Susanne Neumann; Martin Hlavica; Fredrik Piehl; Benjamin V Ineichen Journal: J Neurol Date: 2020-06-13 Impact factor: 4.849